Special Drug Use-results Surveillance for long term administration of XEPLION (Paliperidone Palmitate 1 month formulation), 25mg/ 50mg/ 75mg/ 100mg/ 150mg syringe
Not Applicable
- Conditions
- Schizophrenia
- Registration Number
- JPRN-UMIN000018665
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 1050
Inclusion Criteria
Not provided
Exclusion Criteria
N/A
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method